Product Candidates

 

Product Candidate	Indication(s)	Description	Development Status
Zelrix	Acute migraine	Sumatriptan single-use transdermal patch.	Expected NDA submission during fourth quarter of 2010.   Pivotal Phase III clinical trial completed.   Two ongoing Phase III safety trials.   Two ongoing pharmacokinetic trials in healthy subjects.
NP201	Parkinson’s Disease	Ropinirole two-month implant.	Expected Investigational New Drug submission during first half of 2011.   Preclinical proof of concept completed.
NP202	Schizophrenia and Bipolar Disorder	Atypical antipsychotic three-month implant.	Expected Investigational New Drug submission expected in 2012.   Prototype development in progress.